Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.

NCT04490421 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Lung Neoplasm
Small Cell Lung Cancer
PD-1 Inhibitors

Interventions

DRUG: Camrelizumab combined with Apatinib, Etoposide and Cisplatin

Sponsor

Fuzhou General Hospital